98%
921
2 minutes
20
No vaccines and few chemoprophylaxis options exist for the prevention of bacterial sexually transmitted infections (STIs) (specifically syphilis, chlamydia, and gonorrhea). These infections have increased in the United States and disproportionately affect gay, bisexual, and other men who have sex with men (MSM) and transgender women (TGW). In three large randomized controlled trials, 200 mg of doxycycline taken within 72 hours after sex has been shown to reduce syphilis and chlamydia infections by >70% and gonococcal infections by approximately 50%. This report outlines CDC's recommendation for the use of doxycycline postexposure prophylaxis (doxy PEP), a novel, ongoing, patient-managed biomedical STI prevention strategy for a selected population. CDC recommends that MSM and TGW who have had a bacterial STI (specifically syphilis, chlamydia, or gonorrhea) diagnosed in the past 12 months should receive counseling that doxy PEP can be used as postexposure prophylaxis to prevent these infections. Following shared decision-making with their provider, CDC recommends that providers offer persons in this group a prescription for doxy PEP to be self-administered within 72 hours after having oral, vaginal, or anal sex. The recommended dose of doxy PEP is 200 mg and should not exceed a maximum dose of 200 mg every 24 hours.Doxy PEP, when offered, should be implemented in the context of a comprehensive sexual health approach, including risk reduction counseling, STI screening and treatment, recommended vaccination and linkage to HIV PrEP, HIV care, or other services as appropriate. Persons who are prescribed doxy PEP should undergo bacterial STI testing at anatomic sites of exposure at baseline and every 3-6 months thereafter. Ongoing need for doxy PEP should be assessed every 3-6 months as well. HIV screening should be performed for HIV-negative MSM and TGW according to current recommendations.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11166373 | PMC |
http://dx.doi.org/10.15585/mmwr.rr7302a1 | DOI Listing |
J Int AIDS Soc
September 2025
Centro de Investigación Interdisciplinaria en Sexualidad SIDA y Sociedad, Universidad Peruana Cayetano Heredia, Lima, Peru.
Introduction: Syphilis remains a public health concern in Peru. Pre-exposure prophylaxis (PrEP) implementation programmes in Latin America need to assess their impact on sexually transmitted infections (STIs), along with their feasibility. We assessed the relationship between PrEP adherence and syphilis incidence among men who have sex with men (MSM) and transgender women (TW) enrolled in ImPrEP, a multi-country PrEP demonstration project; however, this analysis focuses on Peru.
View Article and Find Full Text PDFAIDS Behav
August 2025
Division of Infectious Diseases, Columbia University Irving Medical Center, New York, NY, USA.
We iteratively designed a novel patient decision aid (PDA) to improve patient-provider communication regarding the benefits, risks, and proper usage of doxycycline as post-exposure prophylaxis (Doxy-PEP). We tested the feasibility, acceptability, and appropriateness of counseling using this PDA among a pilot group in two academic, urban sexual health clinics. Using a pretest-posttest model we assessed the extent to which this intervention impacted participants' knowledge of and attitudes towards Doxy-PEP.
View Article and Find Full Text PDFBMC Public Health
August 2025
Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing, 210042, China.
Background: Doxycycline post-exposure prophylaxis (Doxy-PEP) represents an emerging strategy for STI prevention. Self-administered use of Doxy-PEP has been empirically observed among men who have sex with men (MSM) in some countries, while little is known about current use of it in the Chinese population.
Methods: An online survey was conducted among MSM in two cities in China.
Am J Public Health
August 2025
Simian Huang, Joshua Klein, Daniela Quigee, Kathrine Meyers, Jacob McLean, Magdalena E. Sobieszczyk, Delivette Castor, and Jason Zucker are with the Division of Infectious Diseases, Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, NY. Natalie Neu is w
This prospective cohort study evaluated the real-world effectiveness of doxycycline postexposure prophylaxis use in reducing bacterial sexually transmitted infections (STIs) within a diverse urban sexual health program. Propensity-matched analyses showed significant STI reductions, particularly in rectal infections, among early adopters. Uptake was disproportionately higher in non-Hispanic White individuals and those more engaged in care.
View Article and Find Full Text PDFBMJ Open
August 2025
Dermatology Hospital of Southern Medical University, Guangzhou, China
Introduction: Doxycycline postexposure prophylaxis (doxy-PEP) can prevent sexually transmitted infections (STIs) among men who have sex with men (MSM) and transgender women (TGW). STI rates are high among MSM and TGW in China, and implementation strategies are needed to optimise doxy-PEP services. Pay-it-forward and social network distribution approaches may increase uptake of STI services and could increase the uptake of doxy-PEP.
View Article and Find Full Text PDF